Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Strong Trading Volume – Here’s What Happened

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw an uptick in trading volume on Friday . 31,899 shares were traded during mid-day trading, an increase of 94% from the previous session’s volume of 16,471 shares.The stock last traded at $10.43 and had previously closed at $10.6750.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The firm’s 50 day moving average is $10.96 and its two-hundred day moving average is $10.67. The stock has a market capitalization of $3.22 billion and a PE ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.